Janus Henderson Group’s Karyopharm Therapeutics KPTI Stock Holding History

Janus Henderson Group’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,537	Closed	-$68.3K	–	2580
2023 Q2	$68.3K	Sell	2,537 -4	-0.2%	-$172	﹤0.01%	2581
2023 Q1	$148K	Buy	2,541 +1,728	+213%	+$85.3K	﹤0.01%	2562
2022 Q4	$41.5K	Hold	813	–	–	﹤0.01%	2428
2022 Q3	$66K	Sell	813 -2	-0.2%	-$149	﹤0.01%	2100
2022 Q2	$55K	Buy	815 +4	+0.5%	+$367	﹤0.01%	2546
2022 Q1	$90K	Hold	811	–	–	﹤0.01%	2576
2021 Q4	$78K	Buy	+811	New	+$80.8K	﹤0.01%	2519
2020 Q2	–	Sell	-216,855	Closed	-$62.5M	–	1353
2020 Q1	$62.5M	Buy	+216,855	New	+$59.8M	0.04%	393

Other funds holding KPTI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Janus Henderson Group's KPTI Position: Q3 2023 in Review

Janus Henderson Group sold out of Karyopharm Therapeutics (KPTI) in Q3 2023, closing a stake of 2,537 shares — an estimated $68.3K sold.

Janus Henderson Group first reported a position in KPTI in Q1 2020 and held it in 8 quarters. The position peaked at $62.5M in Q1 2020. 118 funds tracked by Wall St. Rank hold KPTI as of Q3 2023.

Janus Henderson Group reported no remaining Karyopharm Therapeutics position as of Q3 2023 after selling out during the quarter.
Janus Henderson Group sold 2,537 Karyopharm Therapeutics shares in Q3 2023, an estimated $68.3K.
Janus Henderson Group first reported a position in Karyopharm Therapeutics in Q1 2020 and held it in 8 quarters.
Janus Henderson Group's Karyopharm Therapeutics position peaked at $62.5M in Q1 2020.
118 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2023.

Based on Janus Henderson Group's 13F filing for Q3 2023, filed 14 Nov 2023.